FDMT

4D Molecular Therapeutics, Inc.

FDMT · CIK 1650648 · Annual (10-K) · Last 5 years

Financial Trends

Revenue$0M
20202024
Net Income−$161M
20202024
Operating CF−$135M
20202024
Free Cash Flow−$138M
20202024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue—————
Gross Profit—————
R&D Expense—————
SG&A Expense—————
Operating Income$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B
Net Income$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B
EPS (Basic)$-2.98$-2.58$-3.32——
EPS (Diluted)$-2.98$-2.58$-3.32——

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.6B$0.3B$0.3B$0.4B$0.3B
Current Assets$0.4B$0.3B$0.2B$0.3B$0.3B
Cash & Equivalents$0.1B$0.2B$0.1B$0.2B$0.3B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.5B$0.3B$0.2B$0.3B$0.3B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B
Investing Cash Flow$-0.3B$0.1B$-0.0B$-0.2B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.3B$0.2B$0.0B$0.1B$0.3B
← Companies